Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
|Slideshows|March 26, 2021
You Spoke, We Listened. Psychiatry's Cannabis Survey
Author(s)Psychiatric Times Editors
Enlightening survey results reveal what psychiatrists think about medical marijuana/cannabis use, how or whether to discuss with their patients, and what biases might get in the way of such conversations.
Advertisement
Advertisement
Related to this article
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
4
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
5